UBS Group
NXLIW

UBS Group’s Nexalin Technology Inc Warrant NXLIW Stock Holding History

UBS Group’s Portfolio NXLIW Stock Details NXLIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-105,909
Closed -$4.98K – 10744
2025
Q2 		$4.98K Sell
105,909
-1,273
-1% -$164 ﹤0.01% 9220
2025
Q1 		$19K Buy
107,182
+76,528
+250% +$20.4K ﹤0.01% 8269
2024
Q4 		$10.7K Buy
30,654
+9,912
+48% +$3.59K ﹤0.01% 8281
2024
Q3 		$1.56K Buy
20,742
+3,596
+21% +$606 ﹤0.01% 8607
2024
Q2 		$5.83K Buy
17,146
+17,059
+19,608% +$3.7K ﹤0.01% 7962
2024
Q1 		$4 Sell
87
-28
-24% -$1 ﹤0.01% 9154
2023
Q4 		$1 Buy
+115
New +$2 ﹤0.01% 9207
2023
Q2 		– Sell
-99
Closed -$9 – 9421
2023
Q1 		$9 Sell
99
-601
-86% -$81 ﹤0.01% 9468
2022
Q4 		$140 Sell
700
-2,470
-78% -$445 ﹤0.01% 10359
2022
Q3 		$1K Buy
+3,170
New +$634 ﹤0.01% 9997

UBS Group's NXLIW Position: Q3 2025 in Review

UBS Group sold out of Nexalin Technology Inc Warrant (NXLIW) in Q3 2025, closing a stake of 105,909 shares — an estimated $4.98K sold.

UBS Group first reported a position in NXLIW in Q3 2022 and held it in 10 quarters. The position peaked at $19K in Q1 2025. 0 funds tracked by Wall St. Rank hold NXLIW as of Q3 2025.

  • UBS Group reported no remaining Nexalin Technology Inc Warrant position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 105,909 Nexalin Technology Inc Warrant shares in Q3 2025, an estimated $4.98K.
  • UBS Group first reported a position in Nexalin Technology Inc Warrant in Q3 2022 and held it in 10 quarters.
  • UBS Group's Nexalin Technology Inc Warrant position peaked at $19K in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Nexalin Technology Inc Warrant as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.